Fruman, David A. - University of California, Irvine - Department of Molecular Biology and Biochemistry

研究领域

signal transduction, immunology, cancer, leukemia, kinase, microarray

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Deng, C, Lipstein, MM, Scott, L, Serrano, XO, Mangone, MA, Li, S, Vendome, J, Hao, Y, Xu, X, Deng, SX, Realubit, RB, Tatonetti, NP, Karan, C, Lentzsch, S, Fruman, DA, Honig, B, Landry, DW, O’Connor, OA. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kdelta and CK1epsilon in hematological malignancies. 2016. Blood, Epub Oct. 26. Pai, C, Walsh, CM, Fruman, DA. Context-specific function of S6K2 in helper T cell differentiation. 2016. J. Immunol., Epub Sept. 9. Hong, CA, Cho, SK, Edson, JA, Kim, J, Ingato, D, Pham, B, Chuang, A, Fruman D, Kwon, YJ. Viral/Nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing. 2016. ACS Nano, Epub Aug 5. Zeng, Z, Wang, RY, Qiu, YH, Mak, DH, Coombes, K, Yoo, SY, Zhang, Q, Jessen, K, Liu, Y, Rommel, C, Fruman, DA, Kantarjian, HM, Kornblau, SM, Andreeff, M, Konopleva, M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. 2016. Oncotarget, Epub July 4 So, L, Lee, J, Palafox, M, Mallya, S, Woxland, C, Arguello, M, Truitt, M, Sonenberg, N, Ruggero, D, Fruman, DA. The 4E-BP/eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. 2016. Science Signaling, 9: ra57 Fruman, DA. mTOR signaling: New networks for ALL. 2016. Blood, 127:2658-9. Lee, JS, Vo, TT, Fruman, DA. Targeting mTOR for the treatment of B cell malignancies. 2016. Br. J. Clin. Pharmacol., 82: 1213-1228 Lee, JS, Tang, SS, Ortiz, V, Vo, TT, Fruman, DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. 2015. Oncotarget, 6: 35202-17. Beagle, BR, Nguyen, D, Mallya, S, Tang, SS, Lu, M, Zeng, A, Konopleva, M, Vo, TT, Fruman, DA. mTOR inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. 2015. Oncotarget, 6: 2088-100. Limon, JJ, So, L, Jellbauer, S, Chiu, H, Corado, J, Sykes, S, Raffatellu, M, Fruman, DA. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. 2014. PNAS, Epub Nov. 10